A 56% reduction in flare risk — hazard ratio 0.44, p=0.0005 — across 194 patients is the number Zenas BioPharma needed to carry a BLA to the FDA, and INDIGO delivered it with room to spare. The trial, now simultaneously published in the New England Journal of Medicine and presented at EULAR 2026, was already the largest clinical trial ever conducted in IgG4-RD, and the data package is substantial enough that Zenas submitted its BLA in May before the NEJM publication landed.
The clinical story goes well beyond the primary endpoint. All four key secondary endpoints hit statistical significance. Obexelimab cut the annualized adjudicated flare rate by 52% — 36 events versus 72 in the placebo arm — and 37.1% of treated patients achieved complete remission at Week 52 compared with 19.6% on placebo. The glucocorticoid data are arguably the most clinically consequential: mean cumulative rescue steroid use was approximately 600 mg lower in the obexelimab arm, and the proportion of patients crossing predefined toxicity thresholds on the Glucocorticoid Toxicity Index was meaningfully lower across body weight, glucose, lipid, blood pressure, and infection domains. That steroid-sparing signal matters for a disease historically managed with prolonged glucocorticoid courses. Obexelimab’s mechanism — dual engagement of CD19 and the inhibitory receptor FcγRIIb to suppress B-cell activation without depleting the compartment entirely — kept mean B-cell levels above the lower limit of normal throughout the trial, which plausibly underlies the clean safety readout: Grade ≥3 adverse events ran 11.3% on drug versus 23.7% on placebo.
The competitive context is real. Uplizna (inebilizumab) received FDA approval for IgG4-RD in April 2025, with MITIGATE data showing an 87% flare-risk reduction versus placebo — a larger point estimate than INDIGO’s 56%. Direct cross-trial comparisons are treacherous given different patient populations, rescue-therapy definitions, and flare adjudication rules, but regulators and payers will make them anyway. Where obexelimab can credibly distinguish itself is on route of administration and steroid co-administration: the drug is self-administered subcutaneously at home, weekly, without the glucocorticoid prophylaxis required ahead of IV B-cell-depleting infusions. For patients managing a chronic, relapsing disease across years, that logistical difference is not trivial.
The BLA is now in FDA hands. The single marker worth tracking is the agency’s decision on whether obexelimab’s steroid-toxicity data — measured with the validated Glucocorticoid Toxicity Index across eight clinical domains — earns a label claim beyond simple flare reduction. A GTI-based label statement would give Zenas a concrete differentiating line that trial hazard ratios alone cannot provide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
